When tested in heterotopic U251 GBM and colorectal cancer xenograft models, the combination of CP-DN-ATF5 with ABT263 significantly reduced tumor growth compared with either agent alone and did not show evident side effects. The gene discussed is ATF5; the disease is neoplasm.